TY - JOUR
T1 - (S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology
AU - Moutal, Aubin
AU - Chew, Lindsey A.
AU - Yang, Xiaofang
AU - Wang, Yue
AU - Yeon, Seul Ki
AU - Telemi, Edwin
AU - Meroueh, Seeneen
AU - Park, Ki Duk
AU - Shrinivasan, Raghuraman
AU - Gilbraith, Kerry B.
AU - Qu, Chaoling
AU - Xie, Jennifer Y.
AU - Patwardhan, Amol
AU - Vanderah, Todd W.
AU - Khanna, May
AU - Porreca, Frank
AU - Khanna, Rajesh
N1 - Publisher Copyright:
© 2016 International Association for the Study of Pain.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.
AB - Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.
KW - (S)-lacosamide
KW - CRMP2
KW - CaV2.2
KW - Calcium imaging
KW - Constellation pharmacology
KW - Neuropathic pain
KW - Postoperative pain
UR - http://www.scopus.com/inward/record.url?scp=84976370483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84976370483&partnerID=8YFLogxK
U2 - 10.1097/j.pain.0000000000000555
DO - 10.1097/j.pain.0000000000000555
M3 - Article
C2 - 26967696
AN - SCOPUS:84976370483
SN - 0304-3959
VL - 157
SP - 1448
EP - 1463
JO - Pain
JF - Pain
IS - 7
ER -